Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31563510 | 0.89 | NPC1 (0.50) | MAPTHTTSMN1; SMN2POLBPKM | |
| SCHEMBL31563093 | 0.87 | MAPT (0.50) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL31563030 | 0.84 | ALDH1A1 (0.43) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL31563118 | 0.83 | MAPT (0.45) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL14921880 | 0.82 | RAB9A (0.50) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL31080641 | 0.81 | KMT2A (0.48) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL31552639 | 0.79 | KCNMA1 (0.49) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4621411 | 0.79 | ALDH1A1 (0.49) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL4621414 | 0.79 | ALDH1A1 (0.49) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL31563055 | 0.78 | RAB9A (0.35) | MAPTMEN1KMT2AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199939-B2 | Quinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| WO-2011084368-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRM2 | MAPT 432/4885MEN1 3277/4885KMT2A 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.